Jed Black Selected Research

Disorders of Excessive Somnolence (Hypersomnia)

1/2022	Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia.
3/2021	The Xyrem® (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017.
1/2020	Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.
1/2020	Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy.
1/2020	Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy.
1/2020	Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial.
1/2018	Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.
12/2017	Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy.
1/2017	Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy.
1/2016	Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jed Black Research Topics

Disease

37	Narcolepsy 01/2022 - 10/2002
15	Cataplexy 01/2022 - 10/2002
15	Sleepiness 01/2022 - 11/2004
15	Disorders of Excessive Somnolence (Hypersomnia) 01/2022 - 10/2002
10	Obstructive Sleep Apnea 01/2022 - 10/2002
7	Sleep Initiation and Maintenance Disorders (Insomnia) 08/2017 - 10/2002
5	Nausea 01/2019 - 05/2006
5	Headache (Headaches) 01/2019 - 05/2006
4	Sleep Apnea Syndromes (Sleep Apnea) 01/2019 - 01/2003
3	Nasopharyngitis 01/2019 - 01/2018
2	Muscle Weakness 01/2022 - 09/2005
2	Idiopathic Hypersomnia 01/2022 - 01/2022
2	Sleep Wake Disorders 01/2022 - 10/2002
2	Dizziness (Lightheadedness) 01/2018 - 05/2006
1	Enuresis 01/2018
1	Vomiting 01/2018
1	Psychotic Disorders (Schizoaffective Disorder) 01/2018
1	Diarrhea 07/2016
1	Airway Obstruction (Choking) 02/2013
1	Apnea 10/2008
1	Bradycardia 01/2007
1	Syncope (Fainting) 01/2007
1	Body Weight (Weight, Body) 05/2006
1	Fatigue 05/2006
1	Mood Disorders (Mood Disorder) 05/2006
1	Migraine Disorders (Migraine) 05/2006
1	Duodenal Ulcer (Curling's Ulcer) 05/2006
1	Ulcerative Colitis 05/2006
1	Fibromyalgia (Fibrositis) 01/2006
1	Sleep Deprivation 09/2005
1	Parkinson Disease (Parkinson's Disease) 10/2002
1	Prader-Willi Syndrome (Syndrome, Prader-Willi) 10/2002
1	Restless Legs Syndrome (Restless Legs) 10/2002
1	Type C Niemann-Pick Disease (Niemann Pick Disease, Type C) 10/2002
1	Nervous System Diseases (Neurological Disorders) 10/2002

Drug/Important Bio-Agent (IBA)

24	Sodium Oxybate (gamma Hydroxybutyrate)FDA Link 01/2022 - 11/2004
10	solriamfetolIBA 01/2022 - 07/2016
8	Modafinil (Provigil)FDA Link 01/2020 - 01/2003
5	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2020 - 02/2017
5	OrexinsIBA 08/2017 - 10/2002
4	Dopamine (Intropin)FDA LinkGeneric 01/2020 - 01/2019
4	Pharmaceutical PreparationsIBA 01/2018 - 05/2006
3	SolutionsIBA 01/2022 - 01/2018
2	NexusIBA 01/2021 - 01/2021
2	almorexantIBA 08/2017 - 02/2017
1	Antidepressive Agents (Antidepressants)IBA 01/2022
1	Serotonin (5 Hydroxytryptamine)IBA 02/2017
1	Orexin Receptor AntagonistsIBA 02/2017
1	Tricyclic Antidepressive Agents (Tricyclic Antidepressants)IBA 02/2017
1	BenzodiazepinesIBA 02/2017
1	Hypnotics and Sedatives (Sedatives)IBA 02/2017
1	Anti-Anxiety Agents (Anxiolytics)IBA 02/2017
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 02/2017
1	Oxygen (Dioxygen)IBA 10/2008
1	indiplonIBA 06/2007
1	Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone (FCCP)IBA 02/2007
1	HLA-DQ Antigens (HLA-DQ)IBA 10/2002
1	Psychotropic Drugs (Psychoactive Drugs)IBA 10/2002
1	HLA-DQB1 antigen (HLA DQB1)IBA 10/2002
1	Biological ProductsIBA 10/2002

Therapy/Procedure

10	Therapeutics 01/2022 - 12/2002
3	Continuous Positive Airway Pressure 09/2013 - 05/2006
1	Oral Administration 02/2017
1	Plasmapheresis 09/2005